LCD L36951: MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™) — CGS
Policy LCD-L36951 · Oncology
New LCD could streamline billing for Oncotype DX tests in DCIS.
Code intelligence
D05.9 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code D05.9.
Elevated code riskView ICD-10 detail
Signal breakdown
4 shown · 4 total in platform
Risk: Elevated
0
Critical
0%
1
High
25%
3
Routine
75%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
Routine
LCD L36947: MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™) — Noridian
Policy LCD-L36947 · Oncology
New billing guidelines for Oncotype DX® can impact reimbursement.
LCD L36941: MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™) — Noridian
Policy LCD-L36941 · Oncology
compliance updates for Oncotype DX® starting 02/05/2026
Proposed LCD DL40246: MolDX: Biomarker Testing for Risk Stratification in DCIS — CGS
Policy LCD-DL40246 · Oncology
New LCD could enhance coverage for DCIS biomarker tests.
Audit documentation
Building an audit file that includes D05.9?
The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Oncology audit pack — $349One-time purchase · not a subscription